The PRESIDE trial: A randomized, double-blind, placebo-controlled phase III efficacy and safety study of continued enzalutamide plus docetaxel after disease progression on enzalutamide alone in patients with metastatic castration-resistant prostate cancer

Category Primary study
JournalJournal of Clinical Oncology
Year 2015
This article has no abstract
Epistemonikos ID: 6da440dca587d98b37ac9177cfc1bf02ad28d458
First added on: Feb 07, 2025